Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,040 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
DOLAMA 200: Effectiveness and Safety of a Dual Therapy with Dolutegravir Plus Lamivudine in Treatment-Experienced HIV-1 Infected Real World Participants in Spain.
Sequera-Arquelladas S, Hidalgo-Tenorio C, López-Cortés L, Gutiérrez A, Santos J, Téllez F, Omar M, Ferra-Murcia S, Fernández E, Javier R, García-Vallecillos C, Pasquau J. Sequera-Arquelladas S, et al. Among authors: santos j. Viruses. 2024 Feb 6;16(2):259. doi: 10.3390/v16020259. Viruses. 2024. PMID: 38400035 Free PMC article.
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Hidalgo-Tenorio C, Cortés LL, Gutiérrez A, Santos J, Omar M, Gálvez C, Sequera S, Jesús SE, Téllez F, Fernández E, García C, Pasquau J. Hidalgo-Tenorio C, et al. Among authors: santos j. Medicine (Baltimore). 2019 Aug;98(32):e16813. doi: 10.1097/MD.0000000000016813. Medicine (Baltimore). 2019. PMID: 31393412 Free PMC article.
Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
Palacios R, Mayorga M, González-Domenech CM, Hidalgo-Tenorio C, Gálvez C, Muñoz-Medina L, de la Torre J, Lozano A, Castaño M, Omar M, Santos J. Palacios R, et al. Among authors: santos j. J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218760847. doi: 10.1177/2325958218760847. J Int Assoc Provid AIDS Care. 2018. PMID: 29529910 Free PMC article.
Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study).
Pasquau J, de Jesus SE, Arazo P, Crusells MJ, Ríos MJ, Lozano F, de la Torre J, Galindo MJ, Carmena J, Santos J, Tornero C, Verdejo G, Samperiz G, Palacios Z, Hidalgo-Tenorio C; RIDAR Study Group. Pasquau J, et al. Among authors: santos j. BMC Infect Dis. 2019 Feb 28;19(1):207. doi: 10.1186/s12879-019-3817-6. BMC Infect Dis. 2019. PMID: 30819101 Free PMC article.
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort.
Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Pérez AB, et al. Among authors: santos j. PLoS One. 2019 Aug 30;14(8):e0221231. doi: 10.1371/journal.pone.0221231. eCollection 2019. PLoS One. 2019. PMID: 31469856 Free PMC article.
Weight changes after first-line antiretroviral initiation in a cohort of HIV-positive patients in Southern Spain (CAPOTA study).
Gómez-Ayerbe C, Palacios R, Mayorga M, Navarrete MN, Ferra S, Ruiz I, Garcia C, Castaño M, Merino D, Collado A, Hidalgo-Tenorio C, Delgado M, Rivero A, Santos J. Gómez-Ayerbe C, et al. Among authors: santos j. Int J STD AIDS. 2022 Nov;33(13):1119-1123. doi: 10.1177/09564624221125356. Epub 2022 Sep 7. Int J STD AIDS. 2022. PMID: 36071543
Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort.
Álvarez-Ossorio MJ, Sarmento E Castro R, Granados R, Macías J, Morano-Amado LE, Ríos MJ, Merino D, Álvarez EN, Collado A, Pérez-Pérez M, Téllez F, Martín JM, Méndez J, Pineda JA, Neukam K; HEPAVIR-DAA, GEHEP-MONO, RIS-HEP07 and RIS-HEP13 Study Groups. Álvarez-Ossorio MJ, et al. J Viral Hepat. 2018 Jun;25(6):699-706. doi: 10.1111/jvh.12867. Epub 2018 Feb 27. J Viral Hepat. 2018. PMID: 29377515
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB, Chueca N, García-Deltoro M, Martínez-Sapiña AM, Lara-Pérez MM, García-Bujalance S, Aldámiz-Echevarría T, Vera-Méndez FJ, Pineda JA, Casado M, Pascasio JM, Salmerón J, Alados-Arboledas JC, Poyato A, Téllez F, Rivero-Juárez A, Merino D, Vivancos-Gallego MJ, Rosales-Zábal JM, García F; GEHEP-004 Study Group. Pérez AB, et al. J Hepatol. 2019 Nov;71(5):876-888. doi: 10.1016/j.jhep.2019.06.022. Epub 2019 Jul 4. J Hepatol. 2019. PMID: 31279901
Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy.
Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, Camacho A, Marquez-Solero M, Santos J, García-Lazaro M, Viciana P, Rodriguez-Baños J, Ocampo A. Lopez-Cortes LF, et al. Among authors: santos j. Ther Drug Monit. 2007 Apr;29(2):171-6. doi: 10.1097/FTD.0b013e31803bb54e. Ther Drug Monit. 2007. PMID: 17417070
Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Santos J, Palacios R, Lozano F, López M, Gálvez MC, de la Torres J, López-Cortés LF, Ríos MJ, Rivero A; Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI). Santos J, et al. AIDS Res Hum Retroviruses. 2008 Jan;24(1):24-6. doi: 10.1089/aid.2007.0142. AIDS Res Hum Retroviruses. 2008. PMID: 18275344 Free article. Clinical Trial.
9,040 results